MarketCap
Agios Pharmaceuticals AGIO
$ 33.6
0.16%
Facebook
X
Telegram
Agios Pharmaceuticals Retained Earnings | AGIO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -562 M | -149 M | -823 M | -471 M | -239 M | -1.84 B | -1.52 B | -1.1 B | -798 M | -483 M | -285 M | -167 M | -113 M | -74 M | -53.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -53.9 M | -1.84 B | -579 M |
Quarterly Retained Earnings Agios Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -762 M | -661 M | -562 M | -454 M | -350 M | -238 M | -149 M | -52.4 M | -1 B | -904 M | -823 M | -727 M | -635 M | -552 M | -471 M | -507 M | - | -334 M | -239 M | -144 M | -55.4 M | 30.8 M | -1.84 B | -1.84 B | -1.84 B | -1.84 B | -1.52 B | -1.52 B | -1.52 B | -1.52 B | -1.1 B | -1.1 B | -1.1 B | -1.1 B | -798 M | -798 M | -798 M | -798 M | -483 M | -483 M | -483 M | -483 M | -285 M | -285 M | -285 M | -285 M | -167 M | -167 M | -167 M | -167 M | -113 M | -113 M | -113 M | -113 M | -74 M | -74 M | -74 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.8 M | -1.84 B | -626 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
-3.54 B | - | - | - |  Russia |
 |
AbbVie
ABBV
|
-15.5 B | $ 257.12 | 0.86 % | $ 455 B |  USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 10.89 | 4.11 % | $ 3.25 B |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
-233 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-529 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-321 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.09 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
-742 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
-9.78 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-211 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-720 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
-1.23 B | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-274 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-2.02 B | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-256 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.38 B | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
-436 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-401 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
-1.81 B | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
-418 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-275 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
-260 M | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
-513 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
-978 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
-325 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-572 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
-439 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
|
Cerevel Therapeutics Holdings
CERE
|
-1.4 B | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
-968 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-371 M | - | - | $ 169 M | USA |
 |
Adagene
ADAG
|
-329 M | $ 3.4 | 2.72 % | $ 201 M |  China |
 |
ADC Therapeutics SA
ADCT
|
-1.64 B | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
-90 M | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
-162 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-1.36 B | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
-2.18 B | $ 6.94 | 0.73 % | $ 206 M | USA |